In particular, monoclonal antibodies (mAbs) targeting the PD-1/PD-L1 pathway have resulted in favorable outcomes in advanced bladder cancer and six immune checkpoint inhibitors (ICIs) targeting this pathway were approved in 2015–2018 [7]. The gene discussed is PDCD1; the disease is urinary bladder cancer.